However, existing EGFR-inhibitory drugs used to treat head and neck squamous cell carcinoma, lung cancer, and colorectal cancer have a limited response rate in TNBC 23, 24, and the role of EGFR in CTC clusters and polyclonal metastasis has yet to be studied. This evidence concerns the gene EGFR and colorectal cancer.